Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels

Results From Four Rounds of Ovarian Cancer Screening in a Randomized Trial

(2014) Edward Partridge et al.   OBSTETRICS AND GYNECOLOGY

Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy

(2011) Sadako Nishimura et al.   HUMAN PATHOLOGY

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Proteomics and ovarian cancer: Integrating proteomics information into clinical care

(2010) John L. Hays et al.   Journal of Proteomics

Beyond CA125: the coming of age of ovarian cancer biomarkers

(2009) Dimitra Sasaroli et al.   Biomarkers in Medicine

Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer

(2009) Douglas D. Taylor et al.   GYNECOLOGIC ONCOLOGY

The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?

(2008) Vladimir Nossov et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Use of a Combination of Approaches to Identify and Validate Relevant Tumor-Associated Antigens and Their Corresponding Autoantibodies in Ovarian Cancer Patients

(2008) A. Gagnon et al.   CLINICAL CANCER RESEARCH